Clinical Trial Update: Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders [Phase 3]

View source ↗

Summary

Phase 3 trial assessing PCSK9 inhibition in paediatric patients with genetic LDL disorders has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia

Drugs mentioned

• Prospective PCSK9 inhibitor (unspecified in snippet)

Snippet

Sponsor: Amgen | Conditions: Heterozygous Familial Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2020-07-15